About Lysogene
Lysogene is a company based in Neuilly-sur-seine (France) founded in 2009.. Lysogene has raised $22.61 million across 2 funding rounds from investors including Sarepta Therapeutics, Orbimed and Bpifrance. Lysogene operates in a competitive market with competitors including Spark Therapeutics, Generation Bio, AskBio, Unity Biotechnology and StrideBio, among others.
- Headquarter Neuilly-sur-seine, France
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$22.61 M (USD)
in 2 rounds
-
Latest Funding Round
$8.42 M (USD), Post-IPO
Mar 12, 2020
-
Investors
Sarepta Therapeutics
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Lysogene
Lysogene has successfully raised a total of $22.61M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $8.42 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $8.4M
-
First Round
First Round
(21 May 2014)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2020 | Amount | Post-IPO - Lysogene | Valuation |
investors |
|
| May, 2014 | Amount | Series A - Lysogene | Valuation | Sofinnova Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Lysogene
Lysogene has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Sarepta Therapeutics, Orbimed and Bpifrance. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lysogene
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Lysogene
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lysogene Comparisons
Competitors of Lysogene
Lysogene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spark Therapeutics, Generation Bio, AskBio, Unity Biotechnology and StrideBio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare liver and eye diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| domain | founded_year | HQ Location |
AAV-based gene therapies for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene Therapy to treat CNS diseases such as Parkinson’s disease, ALS.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lysogene
Frequently Asked Questions about Lysogene
When was Lysogene founded?
Lysogene was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Where is Lysogene located?
Lysogene is headquartered in Neuilly-sur-seine, France. It is registered at Neuilly-sur-seine, Ile-de-france, France.
Is Lysogene a funded company?
Lysogene is a funded company, having raised a total of $22.61M across 2 funding rounds to date. The company's 1st funding round was a Series A of $22.61M, raised on May 21, 2014.
What does Lysogene do?
Lysogene was founded in 2009 as a biotechnology firm focused on gene therapy development. Treatments targeting inherited neurodegenerative lysosomal storage disorders, such as mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A), are advanced through adeno-associated virus vectors. The lead candidate, LYS-SAF302, incorporates human N-sulfo glucosamine sulfo hydrolase and has undergone Phase III clinical studies. Additional efforts address GM1 gangliosidosis with AAV-based approaches. Operations center on rare disease therapeutics.
Who are the top competitors of Lysogene?
Lysogene's top competitors include Spark Therapeutics, Generation Bio and AskBio.
Who are Lysogene's investors?
Lysogene has 5 investors. Key investors include Sarepta Therapeutics, Orbimed, Bpifrance, Novo Holdings, and Sofinnova Partners.